Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran - 04/05/22
, Jarl E. Strange, MD a, Peter Vibe Rasmussen, MD, PhD a, Paul Blanche, PhD a, b, Nina Nouhravesh, MD a, Mads Hashiba Jensen, MBSc a, Anne-Marie Schjerning, MD, PhD c, Morten Schou, MD,PhD a, Christian Torp-Pedersen, MD, DMSc d, e, Gunnar H. Gislason, MD, PhD a, f, Morten Lock Hansen, MD, PhD a, Patricia McGettigan, MD, BSc(pharmacy) g, Morten Lamberts, MD, PhD aAbstract |
Background |
Bleeding safety in relation to use of systemic fluconazole and topical azoles among patients with atrial fibrillation treated with apixaban, rivaroxaban, or dabigatran is insufficiently explored, despite clinical relevance and several reports suggesting associations.
Methods |
Using nationwide Danish registers, we identified patients with atrial fibrillation initiated on apixaban, rivaroxaban, or dabigatran from 2012-2018. We investigated associations between bleeding incidents and systemic fluconazole or topical azole treatment using a case-crossover design with 30-day exposure windows and reported odds ratios (OR) with 95% confidence intervals (CI).
Results |
We included 32,340 (36%), 32,409 (36%), and 24,940 (28%) patients initiated on apixaban, rivaroxaban, and dabigatran, respectively. Patients on apixaban were older (median age: 77 years; interquartile range [IQR] 70-84) compared with rivaroxaban users (median age: 75 years; IQR 68-82) and patients on dabigatran (median age: 73 years; IQR 66-80). Apixaban users had a significantly increased risk of bleeding following exposure to systemic fluconazole: odds ratio (OR) 3.5; 95% confidence interval (CI), 1.4-10.6. No increased risk was found among rivaroxaban and dabigatran users: ORs of 0.9 (95% CI, 0.2-3.0) and 1.7 (95% CI, 0.5-5.6), respectively. As to bleeding risk pertaining to topical azole exposure among apixaban, rivaroxaban, and dabigatran users, no association was found, with corresponding ORs of 0.8 (95% CI, 0.5-1.3); 1.3 (95% CI, 0.9-2.1); and 1.2 (95% CI 0.8-1.8), respectively.
Conclusion |
In patients with atrial fibrillation on either apixaban, rivaroxaban, or dabigatran, an association between an elevated bleeding risk and use of systemic fluconazole was found among patients on apixaban. We found no increased risk of bleeding following co-exposure to topical azoles.
Le texte complet de cet article est disponible en PDF.Keywords : Atrial fibrillation, Azole agents, Drug–drug interactions, Drug safety, Fluconazole, NOAC
Plan
| Funding: The lead investigator, AH, and this study have been funded by external, independent grants from “Ib Mogens Kristiansens Almene Fond” (J. nr. 30206-383), “Helsefonden” (20-B-0035) “Snedkermester Sophus Jacobsen og hustru Astrid Jacobsen Fond” (J 167/1), “Marie og M.B. Richters Fond” (J. nr. 2020-0379), and “Dagmar Marshalls Fond.” None of the funds has had any influence on the conduction of this study. |
|
| Conflicts of Interest: CTP declares grants received in relation to a clinical study comparing rivaroxaban and acetyl salicylic acid along with a grant from Novo Nordisk for studying estrogen and endometrial cancer. All other authors declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work. |
|
| Authorship: AH, PM, and ML conceived the study idea. AH, PB, JES, and ML decided on statistical methodology and analyzed the data. All authors contributed to interpretation of the data. AH wrote the first draft of the manuscript. All authors critically revised the manuscript and approved the final version of this manuscript. |
Vol 135 - N° 5
P. 595 - mai 2022 Retour au numéro
Article précédent
- Gastrointestinal Vasoocclusive Crisis in a Woman with Hemoglobin SC Disease
- Jean M. Clement, Andrew Y. Li, Brian W. Berg, Jennie Y. Law, Maria R. Baer
- Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification
- Jamal S. Rana, Salim S. Virani, Howard H. Moffet, Jennifer Y. Liu, Landis A. Coghlan, Jitesh Vasadia, Christie M. Ballantyne, Andrew J. Karter
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?